News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 06 - 16

Efung Mingyuan Seed Fund Lands in Guangming, Focusing on "20+8" Biomedical and High-End Medical Devi

June 10, 2026Shenzhen Efung Mingyuan Seed Venture Investment Partnership (Limited Partnership), established with equity participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its business registration.This milestone marks a critical step forward for Efung Capital in ultra-early-stage investment, and more importantly, signals that Shenzhen's "20+8" industrial clusters have welcomed a new seed fund force that deeply integrates "industrial capital with cutting-edge scientific research."01Precisely Targeting the "20+8" In...

浏览次数：7

查看详情>>

发布时间: 2026 - 06 - 11

World's First Oral Solid Microtubule Stabilizer Receives Phase III Clinical Approval! Breakthrough f

Beijing, China, June 11, 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. (hereinafter referred to as "Biostar", stock code: 2563.HK), a biopharmaceutical company leveraging a synthetic biology R&D platform to focus on developing proprietary anticancer drugs, today announced that its core pipeline product, utidelone capsules (UTD2), has received clinical trial approval (Notice No.: 2026LP01769) from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III clinical study (BG02-2601) in the treatment of HER2-negative advanced breast ...

浏览次数：9

查看详情>>

发布时间: 2026 - 06 - 05

Straight to ASCO 2026 | China's Power Shines Globally, EFUNG Capital's Portfolio Companies Unveil Gr

The annual premier global academic event in oncology — the American Society of Clinical Oncology (ASCO) Annual Meeting — took place as scheduled from May 29 to June 2 local time in Chicago, USA. As one of the most influential academic gatherings in global oncology, ASCO has consistently served as the ultimate proving ground for innovative biotech companies to validate their products. The conference brings together clinicians, researchers, biopharma industry professionals, and media from around the world, spotlighting cutting-edge R&D data on novel cancer drugs and breakthrough results from...

浏览次数：6

查看详情>>

发布时间: 2026 - 05 - 29

Huayuan Regenerative Medicine's Kidney Cell Therapy Receives FDA Orphan Drug Designation

On May 27, 2026, the official website of the U.S. Food and Drug Administration (FDA) announced that ARM101 (Human Renal Progenitor Cell Injection), an hiPSC-derived nephron progenitor cell drug independently developed by Asia Regenerative Medicine Co., Ltd., has officially received Orphan Drug Designation (ODD). The designated indication is for the prevention of Delayed Graft Function (DGF) in kidney transplant recipients. This is the world's first cell therapy targeting DGF to receive FDA Orphan Drug Designation, filling an international gap in the recognition of cell therapy products for...

浏览次数：19

查看详情>>